Moderna on Wednesday said Blackstone’s sciences arm would offer $750 million to help fund development of its flu vaccines, bolstering the company’s efforts to advance multiple vaccines in the face of a steep decline in sales of its COVID-19 shots.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
